

# High Concentration Made Simple



## WHY TROPOCELLS<sup>®</sup> PRP

Tropocells PRP takes the complexity out of the platelet-rich plasma (PRP) preparation process. It delivers a highly purified platelet concentrate that preserves platelets and removes nearly all erythrocytes and neutrophils that promote inflammation.<sup>1</sup>



#### High Concentration

80% (+/- 9%) Platelet Yield + customizable concentrations up to 4.7x\*



#### Safe & Autologous

FDA Cleared 510(k) Class II Medical Device (BK110035) Non-Pyrogenic -Sterile - Closed System

Simple, Quick, & Predictable

Small blood draw, easy to use,

reproducible collection process



### Monocyte Solution

86.2% of white blood cells in PRP preparation are monocytes



V, Tropocells<sup>®</sup> PRP

Tropocells<sup>®</sup> PRP

#### Low Inflammation

Eliminates nearly 100% of red blood cells and 95% of white blood cells



#### Comfortable

Proprietary MNC7 anti-coagulant produces physiologic pH, which reduces irritation<sup>2</sup>

- 1 Simon M. Chatfield, Nathalie Thieblemont, and Véronique Witko-Sarsat. Expanding Neutrophil Horizons: New Concepts in Inflammation. J Innate Immun. 2018; PMID: 30257246 PMCID: PMC6785650 DOI: 10.1159/000493101
- 2 Ehrhardt Proksch. pH in nature, humans and skin. J. Dermatol. 2018 Sep; PMID: 29863755 DOI: 10.1111/1346-8138.14489
- \*Verified in two published peer reviewed studies. 4.7x achieved by removing PPP prior to collecting PRP. Please contact Transcend Biologics representative for copies of these studies.

### FEATURES & BENEFITS

#### Vacuum sealed, internally coated glass tube designed to:

- Prevent platelets from "sticking" to tube walls
- Precisely draw blood at a pressure that prevents lysing of the cells

#### Proprietary anti-coagulant (MNC7) modified to:

- Reduce acidity while preventing coagulation of platelets
- Deliver non-activated platelets physically positioned on top of gel

#### Separator gel designed to:

- Spare up to 80% (+/-9%) of platelets
- Remove 99.9% of RBC
- Remove 95% of granulocytes

### PRP MADE SIMPLE WITH TRANSCEND BIOLOGICS AXIS CENTRIFUGE



Step 1: Draw Blood





Step 2: Spin Tube 3 188 .









### 4 FACTS EVERY PRP PROVIDER SHOULD KNOW

- 1. Platelets release growth factors<sup>1</sup>
- 2. Cytokines can cause tissue damage<sup>2</sup>
- 3. Neutrophils inhibit healing and growth practice<sup>3</sup>
- 4. Monocytes enhance healing<sup>4</sup>

4 José Fábio Lana, Stephany Cares Huber, Joseph Purita, Claudia H. Tambeli, Gabriel Silva Santos, Christian Paulus, and Joyce M. Annichino-Bizzacchi. Leukocyte-rich PRP versus leukocyte-poor PRP - The role of monocyte/macrophage function in the healing cascade. *J Clin Orthop Trauma*. 2019 Oct; PMID: 31700202 PMCID: PMC6823808 DOI: 10.1016/j.jcot.2019.05.008



<sup>1</sup> Eizaburo Kobayashi, Laura Flückiger, Masako Fujioka-Kobayashi, Kosaku Sawada, Anton Sculean, Benoit Schaller, Richard J Miron. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig.* 2016 Dec; PMID: 26809431 DOI: 10.1007/s00784-016-1719-1

<sup>2</sup> A Ferrante, I C Kowanko, E J Bates. Mechanisms of host tissue damage by cytokineactivated neutrophils. *Immunol Ser.* 1992; PMID: 1504146

<sup>3</sup> Erminia Mariani, and Lia Pulsatelli. Platelet Concentrates in Musculoskeletal Medicine. Int J Mol Sci. 2020 Feb; DOI: 10.3390/ijms21041328



## **Optimal PRP Characteristics**

#### OVER 800,000 PATIENT CASES WORLDWIDE SINCE 2013

Brought to you by Transcend Biologics with over 28 years in medical device and Regenerative Medicine.

P L	Tropocells PRP 22mL & 44mL		
Tropocells PRP		22mL	44mL
	Platelet concentration	Зx	4.7x
	RBC %	0.1	0.1
	WBC (10/ul)	0.2	0.2
	Granulocytes %	8.5	8.5
	Mononuclear cells %	86.2	86.2
	PRP Volume	6mL	5mL
	PPP Volume	7mL	21mL



Call 1.833.713.3414

Regulatory status: FDA cleared 510(k) Class II medical device. Tropocells' PRP is intended for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft or allograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK110035